Cancer name HER2-Positive Breast Cancer
Cancer Type BRCA
Immunotherapy type Oncolytic viruses
Treatment Ad5/3-Δ24-tras
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD11c+ DCs
Official Symbol Plasmacytoid dendritic cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Mice sacrificed on day 20 after treatment showed an increase intotal amount of CD11c-positive DCs in tumor-draining lymphnodes when treated with oncolytic Ad5/3-Δ24 or trastuzumab-coding oncolytic Ad5/3-Δ24-tras virus.
PMID 27458139
Title Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer